Treatment Outcome of Irinotecan Monotherapy
スポンサーリンク
概要
- 論文の詳細を見る
During the 1990's many irinotecan monotherapy trials for lung cancer were conducted. Irinotecan monotherapy against previously untreated advanced non-small cell lung cancer showed an overall response rate of 24.5% and median survival time of 6.2 to 10.8 months in 265 patients. There were grade 3 or 4 toxicity of leukopenia (25%), neutropenia (29%), diarrhea (21%), nausea/vomiting (22%) in the treatments. Diarrhea was an especially serious problem. In small cell lung cancer, most patients had been previously treated, yet in this group the overall response rate was 17.6%, with a median survival time of 4.6 to 6.1 months in 118 patients. Clinical trails in previously treated patients with non-small cell and small cell lung cancer are warranted. (JJLC. 2003;43: 832-836)
- 特定非営利活動法人 日本肺癌学会の論文
特定非営利活動法人 日本肺癌学会 | 論文
- 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
- 新潟県における肺がんの解析
- 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
- 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
- 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例